Vertex Pharmaceuticals, VRTX

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a four-day winning streak.
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.12% to 5,842.63 and the Dow Jones Industrial Average DJIA rising 1.14% to 43,006.59.
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks.
TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
Zacks Research Issues Pessimistic Outlook for VRTX Earnings
Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...
Zacks Investment Research on MSN9h
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Editas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Brokers Offer Predictions for VRTX FY2025 Earnings
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
StockNews10d
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
Vertex shares down after Stifel downgrades stock to hold
Inc to “Hold” from “Buy” and lowered its price target to $31 from $35, over the company’s investment strategy and valuation. While Vertex reported solid quarterly, Stifel noted its plan to accelerate ...